Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer

Journal of Proteomics

Volumn 112, Issue , 2015, Pages 301-312

  Fernandez Grijalva A L ^a   Aguilar Lemarroy, A ^b   Jave Suarez, L F ^b   Gutierrez Ortega A ^a   Godinez Melgoza, P A ^a   Herrera Rodriguez S E ^a   Mariscal Ramirez I ^c   Martinez Velazquez M ^a   Gawinowicz, M A ^d   Martinez Silva M G ^c   Cruz Ramos, J A ^e   Hernandez Gutierrez R ^a  

^a CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e Instituto Jalisciense de Cancerología IJC   (Mexico)

Author keywords

A2HS glycoprote n; Autoantibodies; Breast cancer; Early stage; Tumor associated antigen

Indexed keywords

FETUIN A; AUTOANTIBODY; CANCER ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEXICAN; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING; BLOOD; BREAST TUMOR; CANCER STAGING; MASS SPECTROMETRY; METABOLISM; MEXICO; PROCEDURES;

ALPHA-2-HS-GLYCOPROTEIN; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; FEMALE; HUMANS; MEXICO; NEOPLASM STAGING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84910030265     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.07.025     Document Type: Article

References (46)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Ahmedin-Jemal D.V.M., Bray F., Melissa M., Jacques-Ferlay M.E., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Coleman M.P. Trends in breast cancer incidence, survival, and mortality. Lancet 2000, 356:590-591.
4. Cancer incidence in five continents 2007, vol. IX:160. IARC Scientific Publications, Lyon France. M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue (Eds.).
5. De Santis C., Ma J., Bryan L., Ahmedin-Jemal D.V.M. Breast cancer statistics. CA Cancer J Clin August 2013, 00:1-11.
6. Griffiths A.R., Brock A. Twentieth century mortality trends in England and Wales. Office for National Statistics. Health Stat Q 2003, 18:5-17.
7. Tabar L., Fagerberg C.J., Gad A., Baldetorp L., Holmberg L.H., Gröntoft O., et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985, 1:829-832.
8. Jesneck J.L., Mukherjee S., Yurkovetsky Z., Clyde M., Marks J.R., Lokshin A.E., et al. Do serum biomarkers really measure breast cancer?. BMC Cancer 2009, 9:164.
9. Conleya B.A., Taube S.E. Prognostic and predictive markers in cancer. Dis Markers 2004, 20:35-43.
10. Zaenker P., Ziman M.R. Serological autoantibodies as diagnostic cancer biomarkers-a review. Cancer Epidemiol Biomarkers Prev 2013, 22(12):2161-2181.
11. Chapman C., Murray A., Chakrabarti J., Thorpe A., Woolston C., Sahin U., et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007, 18:868-873.
12. Reuschenbanch M., Doeberitz MvK, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009, 58(10):1535-1544.
13. Desmetz C., Bibeau F., Boissiere F. Proteomics based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res 2008, 7:3830-3837.
14. Pereira-Faca S.R., Kuick R., Puravs E., Zhang Q., Krasnoselsky A.L., Phanstiel D., et al. Identification of 14-3-3 θ as an antigen that induces a humoral response in lung cancer. Cancer Res 2007, 67:12000-12006.
15. Park B.W., Oh J.W., Kim J.H., Park S.H., Kim K.S., Kim J.H., et al. Preoperative CA15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008, 19:675-681.
16. Hu S., Loo J.A., Wong D.T. Human body fluid proteome analysis. Proteomics 2006, 6:6326-6353.
17. Downes M.R., Byrne J.C., Dunn M.J., Fitzpatrick J.M., Watson R.W., Pennington S.R. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers 2006, 11:406-416.
18. Chang J.W., Kang U.B., Kim D.H., Yi J.Y., Lee J.W., Noh Y.D., et al. Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin Appl 2008, 2:23-32.
19. Caron M., Choquet-Kastylevsky G., Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics 2007, 6:1115-1122.
20. Fernández-Madrid F. Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumourigenesis. Cancer Lett 2007, 230:187-198.
21. Hong S.H., Misek D.E., Wang H., Puravs E., Giordano T.J., Greenson J.K., et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004, 64:5504-5510.
22. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001, 98:9824-9829.
23. Ren P., Ye H., Dai L., Liu M., Liu X., Chai Y., et al. Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma. Oncol Rep 2013, 30(5):2297.2303.
24. Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., Beretta L. A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis. Molecular & Cellular Proteomics 2002, 1(3):197-203.
25. Fujita Y., Nakanishi T., Hiramatsu M., Mabuchi H., Miyamoto Y., Miyamoto A., et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:6415-6420.
26. Loo K.S., Nakayasu E.S., Díaz R.A., Tan E.M., Almeida I.C., Zhang J.Y. Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res 2008, 7:4004-4012.
27. Volkmann M., Sinn H.P., Gaugel D. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002, 63:297-305.
28. Duffy M.J. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999, 36:579-586.
29. Douglas D.T., Cicek G.T., Lynn P.P. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009, 115:112-120.
30. Tan T.H., Low J., Lim G.S., Chung C.M.M. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
31. Disis M.L., Pupa S.M., Gralow J.R., Dittadi R., Menard S., Cheever M.A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997, 15:3363-3367.
32. Le Naour F., Misek D.E., Krause M.C., Deneux L., Giordano T.J., Scholl S., et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001, 7:3328-3335.
33. Desmetz C., Bascoul-Mollevi C., Rochaix P., Lamy P.J., Kramar A., Rouanet P., et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009, 15:4733-4741.
34. Tamesa M.S., Kuramitsu Y., Fujimoto M., Maeda N., Nagashima Y., Tanaka T., et al. Detection of autoantibodies against cyclophillin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 2009, 30:2168-2181.
35. Tang Y., Wang L., Zhang P., Wei H., Gao R., Liu X., et al. Detection of circulating anti-Mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol 2010, 17(12):1903-1908.
36. López-Árias E.A., Aguilar-Lemarroy A., Jave-Suárez L.F., Morgan-Villela G., Mariscal-Ramírez I., Martínez-Velázquez M., et al. Alpha 1-antitrypsin: a novel tumor-associated antigen (TAA) identified in early stage breast cancer patients. Electrophoresis 2012, 33:2130-2137.
37. David E.M., Evelyn H.K. Protein Biomarkers for the Early Detection of Breast Cancer. International Journal of Proteomics 2011, 2011:9. Article ID 343582. 10.1155/2011/343582.
38. Lacombe J., Mangé A., Jarlier M., Bascoul-Mollevi C., Rouanet P., Lamy P.-J., et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer Mar 1 2013, 132(5):1105-1113.
39. Reuschenbanch M., Kneel Doeberitz M.V., Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother October 2009, 58(10):1535-1544.
40. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology. 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
41. Mori K., Emoto M., Araki T., Yokoyama H., Teramura M., Lee E., et al. Association of serum Fetuin-A with carotid arterial stiffness. Clin Endocrinol 2007, 66:246-250.
42. Dogru T., Genc H., Tapan S., Aslan F., Ercin C.N., Ors F., et al. Plasma Fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol 2013, 78:712-717.
43. Swallow C.J., Partridge E.A., Macmillan J.C., Tajirian T., DiGuglielmo G.M., Hay K., et al. α2HS-Glycoprotein, an antagonist of transforming growth factor β in vivo, inhibits intestinal tumor progression. Cancer Res 2004, 64:6402-6409.
44. Petrik V., Saadoun S., Loosemore A., Hobbs J., Opstad K.S., Sheldon J., et al. Serum α2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008, 54(4):713-722.
45. Ghosh S.K., Pantazopoulos P., Medarova Z., Moore A. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer Apr 2013, 13(2):109-118.
46. Yamaguchi H., Tanaka F., Ohta M., Inoue H., Mori M. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response. Clin Cancer Res Feb 1, 2004, 10:890.